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Abstract 
Mastitis affects a high proportion of dairy cows throughout the world and is one of the greater problems faced by the dairy 
industry today. The disease is still a major cause of economic loss on a dairy farm. Mastitis poses not only negative consequences 
for the dairy farmer but also for the dairy industry as a number of issues threaten the reputation of milk as a healthy product 
from healthy animals. The use of antimicrobials is one of those concerns and threats. Antimicrobial usage on dairy farms is 
most often related to udder health as most medicines are used in prevention and control of mastitis. Antimicrobials remain vital 
for treatment of bacterial infections in dairy cattle, but in light of the upcoming debate instigated by the potential link between 
the use of antimicrobial products in animal husbandry and the development of antimicrobial resistance in both animal and 
human pathogens, there is an urgent need for innovation and alternatives to antibiotic therapy for mastitis treatment and 
control. Alternative approaches include vaccination, probiotics or beneficial microorganisms and inhibitory substances, 
immunomodulation, bacteriophages, homeopathy, and plant-derived inhibitory substances, yet only when scientifically-proven 
evidence is available indicating these alternatives are effective. 
Keywords: Alternative. Mastitis. Treatment. Vaccination. 
 
Resumo 
A mastite ocorre em uma alta proporção de vacas leiteiras em todo o mundo e é um dos grandes problemas que atinge a indústria 
leiteira. A doença ainda é uma das maiores causas de perdas econômicas das granjas leiteiras. A mastite não tem apenas 
consequências negativas para os fazendeiros, mas atinge também a indústria leiteira, particularmente pela expectativa de que o 
leite deve ser um produto saudável produzido por animais saudáveis. O uso de antimicrobianos é uma grande preocupação. O 
emprego de antimicrobianos nas granjas leiteiras está frequentemente relacionado com a saúde do úbere uma vez que a maioria 
dos medicamentos são usados na prevenção e controle da mastite. Os antimicrobianos ainda são vitais para o tratamento das 
infecções bacterianas do gado leiteiro, mas na atualidade há um grande questionamento para a ligação potencial entre o uso de 
produtos antimicrobianos no manejo animal e o desenvolvimento de resistência antimicrobiana tanto de patógenos de animais 
como de humanos, há portanto a necessidade urgente da introdução de alternativas para o tratamento e controle da mastite 
com antibióticos. As possibilidades incluem vacinação, probióticos ou microorganismos benéficos e substâncias inibidoras, 
imunomodulação, bacteriófagos, homeopatia, fitoterápicos inibidores. Contudo todos esses procedimentos necessitam ser 
cientificamente provadas para demonstrar que são alternativas realmente efetivos.  
Palavras-chave: Alternativas. Mastite. Tratamento. Vacinação.  
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Introduction  
Mastitis affects a high proportion of dairy cows 
throughout the world and is one of the greater 
problems faced by the dairy industry today 
(BRADLEY, 2002). The disease is still a major cause of 
economic loss on any dairy farm. The main financial 
losses are due to the expense of antibiotic treatment, 
along with the associated costs of decreased milk 
production and decreased fertility or, in cases where 
antibiotic treatment is ineffective or unwanted, culling 
or death (HALASA et al., 2007). Additionally, farmers 
supplying milk with a high bulk milk somatic cell 
count may be losing out on bonus payments and may 
also incur penalties. Treating infected cows also 
increases labor (e.g. time and effort) for the farmer and 
causes stress, consequences that should not be 
underestimated as both are perceived as the two most 
annoying aspects of mastitis by farmers (JANSEN et 
al., 2009). 
Mastitis has consequences beyond the dairy farm as 
well as a number of issues related to the disease that 
threaten the positive reputation of milk as a healthy, 
high-quality and nutritious product produced by 
healthy and contented animals. First, udder health 
accounts for the largest proportion of antimicrobial 
drug use on a dairy farm (STEVENS et al., 2016). 
Second, herds struggling with udder health problems 
have a higher risk of delivering milk containing 
antibiotic residues because of their increased (and 
often injudicious) antibiotic usage (RUEGG; 
TABONE, 2000). Third, cows suffering from even mild 
cases of clinical mastitis are in pain, which obviously 
has its implications for animal welfare. In fact, because 
of worries about potential antimicrobial residues in 
milk, emerging antimicrobial resistance, issues with 
milk quality and animal welfare, mastitis has become a 
valid concern to consumers and society, a development 
everyone involved in the dairy industry should be 
aware of. 
Ongoing political debate and public concerns about 
the emergence of antimicrobial resistance and drug 
residues in milk emphasize the need for innovation 
and alternatives to antibiotic therapy. The focus of this 
manuscript is to describe and discuss mastitis vaccines 
and alternatives that can potentially be used in the 
prevention and control of bovine mastitis with a focus 
on the potential relevance of medium-chain fatty acids 
(MCFA).  
 
Vaccines 
What is vaccination? 
The immune response of the mammary gland 
consists of an innate and adaptive immune response 
arm. The adaptive immune response arm specifically 
responds to a specific antigen. The innate immune 
system recognizes conserved microbial molecules via 
their receptors (RAINARD; RIOLLET, 2006). Besides 
the macrophages, neutrophils, dendritic cells, and 
natural killer cells, it also includes physical barriers 
such as the teat sphincter, and chemical barriers such 
as the keratin of the teat canal and lactoferrin 
(SCHUKKEN et al., 2011). Interestingly, milk in 
healthy cows has a resident population of immune 
cells. The population is usually dominated by 
macrophages but also contains neutrophils and 
lymphocytes (SORDILLO, 2005). Lymphocytes are 
divided in two groups: T- and B-lymphocytes. The T-
lymphocytes are further categorized into αβ T-
lymphocytes, including CD4+ T-helper lymphocytes 
and CD8+ T-cytotoxic lymphocytes, and γδ T-
lymphocytes. In the lactating mammary gland, αβ T-
lymphocytes dominate and primarily express the CD8+ 
phenotype (SHAFER-WEAVER; SORDILLO, 1996). 
Those activated cytotoxic CD8+ T-lymphocytes kill are 
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assumed to kill host cells infected with a pathogen, as 
detected by antigens expressed on the surface of the 
infected cells. On the contrary, helper CD4+ T-
lymphocytes have a more indirect but equally 
important effect on the invaded mastitis-causing 
pathogens. A CD4+ T-helper lymphocyte that matures 
usually develops into one of four types of T-helper 
cells. Stimulation of the latter mature T-helper cells 
results in the expression of a large variety of cytokines 
that can direct the immune response towards a B-cell-
mediated (Th2 response), a pro-inflammatory 
cytotoxic T-cell-mediated response (Th1 response) or 
a neutrophil-mediated response (Th17 response) or in 
the expression of cytokines that counter-regulate the 
response (Treg response). It is well-known that when 
bacteria invade the mammary gland and cause an 
intramammary infection, large numbers of leukocytes 
migrate into the udder, resulting in the establishment 
of a host response against the pathogen. Although the 
increasing body of research that focuses on the 
immunological response of the mammary gland, the 
specific leukocyte populations mediating this immune 
response are currently not yet well defined.  
Perhaps the most important consequence of an 
adaptive immune response is the establishment of a 
state of immunological memory. Immunological 
memory is the ability of the immune system to respond 
more rapidly and effectively to pathogens that have 
been previously encountered, which happens in case of 
vaccination (JANEWAY et al., 2001). A distinguishing 
feature of immunological memory is the irreversible 
genetic change of B-lymphocytes from IgM producers 
to producers of other antibody isotypes, including 
IgG1 and IgG2 (BURTON et al., 2001). In several 
species including the bovine, an immune response with 
a higher production of IgG2 antibody has been 
recognized as part of a Th1 pro-inflammatory 
response, while a response with a higher production of 
IgG1 is part of a Th2 or anti-inflammatory response. 
Because IgG2 is an important opsonizing antibody 
aiding in neutrophil phagocytosis of bacteria, and IgG2 
has the ability to readily fix complement, it has been 
suggested that an IgG2 Th1-type response might be 
beneficial against bovine mastitis (THOMPSON-
CRISPIE et al., 2013).  
Each vaccine contains a killed or weakened form of 
the specific organism (e.g. Staphylococcus aureus, 
Escherichia coli, …) that causes a disease such as 
mastitis. Even though the organism in the vaccine has 
been altered so that it will not cause sickness, the part 
of the organism that stimulates the immune system to 
respond to (“antigen”) is still present. Mastitis vaccines 
against E. coli primarily contain the inactive J5 E. coli 
strain, resulting in the formation of antibodies against 
the uniform component lipopolysaccharide (LPS) in 
the outer membrane of all Gram-negative bacteria 
causing the severe symptoms associated with 
hyperacute E. coli mastitis cases. Mastitis vaccines 
against S. aureus consist of either bacterins (= killed or 
avirulent/weakened S. aureus strains) or 
exopolysaccharides (= sugar residues secreted by 
bacteria in the surrounding environment). One of 
those exopolysaccharides is poly-N-acetylglucosamine 
(PNAG), a surface polymer produced by a variety of 
bacterial species, including S. aureus and 
Staphylococcus epidermidis, and facilitating bacterial 
cell-to-cell contact in biofilms (PÉREZ et al., 2009).  
 
What is vaccine efficacy? 
Efficacy of a vaccine refers to the reduction in 
disease measured in a carefully monitored, 
randomized controlled clinical trial conducted in a 
homogeneous population according to a defined 
protocol. In essence, the vaccine efficacy is determined 
by four parameters. The first parameter is the impact 
of vaccinations on the rate of new infections. This 
represents the classic vaccine effect, whereby the 
vaccine reduces the susceptibility of non-infected 
individuals such that no or fewer new infections take 
place. The second parameter is the impact of 
vaccination on the infectiousness of an infected 
individual. The vaccine may reduce the amount of 
shedding of infected but vaccinated individuals 
compared to nonvaccinated infectious individuals. For 
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example, considering S. aureus is a mammary 
pathogen that may be transmitted cow-to-cow, a 
reduction in the infectiousness of a vaccinated 
individual would be valuable. The third parameter is 
the impact of vaccination on the cure of existing 
infections. Vaccinations may result in a shorter 
duration of infection. The duration is essentially the 
inverse of cure, so a higher cure will result in a shorter 
duration. The fourth and final parameter of vaccine 
efficacy is the reduction in progression of infection 
from subclinical to clinical mastitis. As clinical mastitis 
results in milk discard, treatment and animal sickness, 
a reduction in progression of infection would be of 
value to the dairy industry.  
 
Vaccines against mastitis 
Commercial mastitis vaccines are currently 
available for immunization against mastitis caused by 
S. aureus and E. coli. In the U.S., there are two S. aureus 
bacterins available. The vaccines are marketed as 
Somato-Staph® and Lysigin® and are labeled as somatic 
antigen containing phage types I, II, III, IV and 
miscellaneous groups of S. aureus. There are also three 
coliform mastitis vaccines available. Two are identical 
and marketed as J-5 Bacterin® (Hygieia Biological 
Laboratories, Woodland, California, USA), 
ENVIRACOR J-5 (Zoetis, Parsippany, New Jersey, 
US). A separate bacterin-toxoid (J-Vac®, Merial Inc., 
Duluth, Georgia, USA) is also available. The 4th Gram-
negative mastitis vaccine contains re-17 mutant 
Salmonella typhimurium bacterin toxoid. On the 
European market, there is only one labeled vaccine 
against mastitis available (Startvac®, Hipra S.A., 
Girona, Spain). The vaccine contains inactivated E. coli 
(J5), inactivated S. aureus (CP8) SP 140 strain 
expressing Slime Associated Antigenic Complex 
(SAAC) and adjuvant. The vaccine has a label claim for 
reducing the incidence of subclinical mastitis and 
incidence and severity of clinical signs of clinical 
mastitis caused by coliform, S. aureus, and non-aureus 
staphylococci (NAS).  
At this time, there are no commercial vaccines 
available that have a proven efficacy against 
streptococcal mastitis. Still, the increased frequency of 
mastitis caused by environmental streptococci such as 
Streptococcus uberis has resulted in a number of 
unsuccessful attempts to produce vaccines against this 
pathogen. The wide strain variety together with the 
strain-specific protection in particular slows the 
development of vaccines specifically oriented against 
mastitis-causing streptococci (DENIS et al., 2009).  
 
Vaccine efficacy 
Vaccine efficacy against S. aureus 
A number of studies have been published on the 
efficacy of vaccination against S. aureus mastitis. In 
one of the first field trials including 30 heifers, a 3-fold 
decreased risk of S. aureus infections was observed in 
heifers vaccinated with an experimental vaccine 
formulation based on inactivated S. aureus cells and 
exopolysaccharides at 5w and 1w before calving. Still, 
no effects on the somatic cell count were found 
(GIRAUDO et al., 1997). Nickerson et al. (1999) 
vaccinated heifers with the commercially available 
Lysigin® (Boehringer Ingelheim Vetmedica Inc., St. 
Joseph, Missouri, USA) at six months of age followed 
by a booster dose two weeks later and subsequent 
vaccinations every six months until calving. 
Vaccinated heifers had a 45% reduction in both new S. 
aureus intramammary infections during pregnancy 
and new S. aureus intramammary infections at calving 
relative to controls. Middleton et al. (2006) compared 
the efficacy of the same commercially available vaccine 
with two experimental formulations and 
nonvaccinated controls in primiparous heifers as well. 
Heifers were vaccinated twice, 28 days apart in late 
gestation with either a 3-isolate experimental bacterin 
(Group I; n = 11), a 5-isolate experimental bacterin 
(Group II; n = 11), or the commercially available 
Lysigin® (Boehringer Ingelheim Vetmedica Inc., St. 
Joseph, Missouri, USA) (Group III; n = 14). Group IV 
consisted of 11 nonvaccinated control animals. All 
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groups (vaccinated animals and nonvaccinated ones) 
were challenged with a heterologous strain of S. aureus 
by intramammary infusion on days 6-8 of lactation in 
a single infection-free mammary quarter. All animals 
became infected with S. aureus after challenge. In 
contrast to the results obtained by Nickerson et al. 
(1999), no differences in S. aureus clearance rates were 
observed between groups. Animals vaccinated with 
Lysigin® (Boehringer Ingelheim Vetmedica Inc., St. 
Joseph, Missouri, USA) had a lower mean duration of 
clinical mastitis and showed less severe symptoms than 
nonvaccinated control animals. There was no evidence 
that any of the vaccinated groups had a lower somatic 
cell count than nonvaccinated control animals, and no 
evidence that vaccinates had a greater milk yield than 
controls post-challenge. Still, significantly higher 
concentrations of milk antibodies against S. aureus 
were observed in the Lysigin® (Boehringer Ingelheim 
Vetmedica Inc., St. Joseph, Missouri, USA) vaccinated 
animals than in the nonvaccinated control animals 
(LUBY et al., 2007). Similar results were obtained in 
studies that used avirulent (PELLIGRINO et al., 2008) 
or inactivated S. aureus (TENHAGEN et al., 2001) 
vaccine formulations or vaccines including insoluble 
bacterial fragments of two field S. aureus field strains 
and secreted antigens of a third field strain (LEITNER 
et al., 2013). In the latter study, however, the milk 
somatic cell count was almost 50% lower in vaccinated 
animals compared to nonvaccinated animals. Also, the 
average daily milk yield was 0.5 kg/day higher in 
vaccinated animals than in nonvaccinated control 
cows.  
In a recently published study (SCHUKKEN et al., 
2014), the efficacy of the novel commercially available 
vaccine Startvac® (Hipra S.A., Girona, Spain) was 
evaluated on two commercial dairy farms. In total, 
1,156 lactations from 809 cows were enrolled. During 
the first phase of the trial, all cows that were due to 
calve were vaccinated until approximately 50% of the 
cows in the milking herd was vaccinated. At that point, 
when 50% vaccination coverage was reached, cows that 
were due to calve were randomly assigned to be 
vaccinated or left as negative controls. Vaccination of 
cows was done according to label, with a total of three 
vaccine doses, with the first injection at 45 days before 
the expected parturition date, the second injection 35 
days thereafter (corresponding to 10 days before the 
expected parturition date), and the third injection 62 
days after the second injection (equivalent to 52 days 
post-parturition). The vaccine efficacy for the rate of 
new infections was relatively low and depending on the 
parity. For heifers, the vaccine efficacy for 
transmission was 25%, indicating that the new 
infection rate was 25% lower in vaccinated heifers than 
in nonvaccinated heifers. However, the vaccine 
efficacy for transmission was still positive but 
nonsignificant for animals in second lactation (+ 16%) 
and even negative (- 30%) for animals in third or 
higher lactation. The latter suggests an even higher 
transmission and thus higher new infection rate in 
vaccinated animals than in nonvaccinated animals. 
The vaccine efficacy for cure was moderate with a value 
of 41%, meaning that the cure rate of S. aureus 
infections in vaccinated animals was 41% higher than 
in nonvaccinated animals. The latter resulted in a 
shorter duration of S. aureus infections. Still, a 
significant difference in vaccine efficacy for cure was 
present between the two herds. Combining the 
transmission parameter and cure rate parameter into 
the overall basic reproduction ratio, R0, resulted in a 
value of 0.89 for vaccinated animals and a value of 1.72 
for control cows. For NAS, the R0 value for vaccinated 
animals was 0.91 and 1.40 for control animals. For both 
NAS and S. aureus, vaccination resulted in moving the 
basic reproduction ratio from above to below the 
threshold of one. The overall vaccine efficacy was 
estimated at 45%.  
In an experimental clinical trial including eight 
clinically healthy heifers and cows, four animals were 
vaccinated with Startvac® (Hipra S.A., Girona, Spain) 
at 45 days and 10 days before calving (PIEPERS et al., 
2017). At 15 days after calving, two contralateral 
quarters of each of the eight animals were challenged 
with 2 x 109 cfu/ml of the formaldehyde-killed S. aureus 
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strain. The other two quarters were infused with a 
phosphate buffered solution and served as control 
quarters. Blood samples were collected at 45 days 
before calving, 10 days before calving and 15 days after 
calving just before inoculation. Quarter milk samples 
were collected at two hours before inoculation and four 
hours, 12 hours, 24 hours and 48 hours after 
inoculation. All animals remained clinically healthy 
during the trial period. Twelve hours post-challenge, 
all quarters inoculated with the killed S. aureus strain 
were PCR-positive for S. aureus. Still, quarters from 
vaccinated animals had odds up to 20 times higher to 
be free of S. aureus two days post-challenge than 
nonvaccinated animals. In the nonvaccinated group, 
the average daily milk yield tended to decrease from 
34.2 kg/day at 15 days after calving to 30.5 kg per day 
at 16 days after calving. In the vaccinated group, no 
significant difference in the average daily milk yield 
was observed over time. On the contrary, the average 
daily milk yield even increased from 33.7 kg per day at 
15 days after calving to 36.5 kg per day at 16 days after 
calving. Interestingly, in the nonvaccinated animals, S. 
aureus-challenged quarters had a significantly higher 
somatic cell count than the control quarters whereas in 
the vaccinated group, the quarter milk somatic cell 
count was not significantly different from the quarter 
milk somatic cell count in the control quarters. The 
milk neutrophil viability was significantly higher in the 
S. aureus-challenged quarters than in the control 
quarters though was not influenced by the vaccination 
status of the animal. The blood concentration of both 
SAAC- and J5-specific antibodies increased between 
45 days before the expected calving date and 15 days 
after calving in the vaccinated animals only. 
Consequently, vaccinated animals had significantly 
higher SAAC- and J5-specific antibody blood 
concentrations at 15 days after calving (pre-challenge) 
than the nonvaccinated animals. The milk 
concentration of SAAC-specific antibodies was 
significantly higher in vaccinated animals than in 
nonvaccinated animals, independently from the 
inoculation status of the quarters and the time of 
sampling. The latter findings support the results of 
Prenafeta et al. (2010). The higher anti-SAAC blood 
concentrations suggest a more pronounced humoral 
specific immune response which might explain the 
shorter duration of the S. aureus infections as was 
found in the study of Schukken et al. (2014). Also, the 
higher anti-SAAC concentrations in milk might 
potentially trigger the opsonization of the inoculated S. 
aureus bacteria and partly explain why vaccinated 
animals suffered from a less severe inflammatory 
reaction than the nonvaccinated animals. In this 
regard, Camussone et al. (2014) immunized 17 
pregnant heifers with one of two vaccine formulations 
composed of either S. aureus whole or lysed cells 
formulated with Immune Stimulation Complex Matrix 
(ISCOM matrix). Both immunogens induced a strong 
humoral immune response in blood and milk 
characterized by a substantial increase in antibody 
concentration. Neutrophil phagocytosis was much 
more pronounced in the vaccinated animals than in 
the nonvaccinated ones, suggesting an increased 
opsonization of the S. aureus bacteria in case of 
increased antibody concentrations. The milk 
concentration of J5-specific antibodies observed in 
vaccinated animals was not significantly different at 15 
or at 17 days after calving. Vaccination with Startvac® 
(Hipra S.A., Girona, Spain) evoked a shift primarily 
toward the IgG1 antibody subtype (Th2-response). 
The IgG1 antibodies are well-known for their strong 
opsonizing capacity facilitating the recognition of the 
bacteria by the immune cells as well as their 
phagocytosis and killing by those immune cells. 
Regarding the response against E. coli, a weak though 
significant increase in J5-specific IgG2 concentrations 
(Th1-response) was observed.  
 
Vaccine efficacy against E. coli 
Despite the development of several vaccines 
against E. coli mastitis in the 1980s, based on the J5 E. 
coli mutant, such vaccines to date, although 
demonstrating an ability to reduce the severity of 
clinical signs and duration of infection, have failed to 
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demonstrate a reduction in the rate of new 
intramammary infections (HOGAN et al., 1992; 
WILSON et al., 2007a). Investigation of the use of J5 
coliform vaccines has also demonstrated a positive 
effect on production in a way that vaccinated cows 
have been shown to recover milk yield after a clinical 
case more quickly than unvaccinated cows (WILSON 
et al., 2007b, 2008, 2009). The latter research group also 
provided evidence that increased production of both 
J5-specific IgG1 and IgG2 antibodies are relevant 
mechanisms of J5 vaccine protection, including the 
production of a higher proportion of IgG2 in 
vaccinated animals than in non-vaccinates which 
points towards a Th1-response. A significant 
constraint on the use of E. coli mastitis vaccines has 
been the relatively onerous vaccination regimens 
necessary to achieve the desired level of efficacy. These 
often necessitate vaccination both before and after 
calving. This has led to the development of more 
practical, farmer-friendly approaches to vaccination 
when J5 core antigen vaccines have been deployed in 
the field, such as a rolling schedule of vaccination of all 
cows in the herd on a quarterly basis. In a recent study, 
the efficacy of a multivalent mastitis vaccine in the 
control of bovine mastitis under UK field conditions 
using both the label regimen and a schedule of 
quarterly vaccination (BRADLEY et al., 2015). 3,130 
cows were recruited between September 2010 and 
January 2012 to develop this study, from seven farms 
in the southwestern United Kingdom, and were 
randomly allocated, within farm, to one of three 
groups. The ﬁrst group received the vaccine (Startvac®, 
Hipra S.A., Girona, Spain) following the label regimen, 
the second group was vaccinated every 90 d following 
an initial vaccination course, and the third group was 
left unvaccinated to act as controls. Vaccine efﬁcacy 
was assessed in the ﬁrst 120 d of lactation. No strict 
criteria were applied pertaining to bulk milk somatic 
cell count or clinical mastitis incidence. All cows and 
heifers approaching their ﬁrst calving were eligible for 
recruitment to the study, contingent on being in good 
health, having four functional quarters, teats free of 
signiﬁcant teat lesions, and an estimated calving date 
to allow vaccination at predicted times before calving. 
Data were available for analysis from 1,696 lactations 
in 1,549 cows. In total, 779 cases of clinical mastitis 
occurred in the three study groups, and no signiﬁcant 
differences were observed in the incidence or 
prevalence of clinical or subclinical mastitis between 
any of the three groups. Mastitis vaccination following 
the label regimen was associated with a signiﬁcant 
reduction in the severity of clinical cases. Cows in this 
group were at signiﬁcantly decreased odds of 
developing moderate to severe clinical mastitis (i.e. 
more than just visual changes of the milk). When the 
analysis was extended with the effect of vaccination on 
culling to encompass the ﬁrst 305 d of lactation, this 
revealed a signiﬁcant difference in the total number of 
cows culled between the treatment groups, with 26.2, 
18.3, and 24.2% of cows being culled in the 
unvaccinated, label, and rolling groups, respectively. 
Significantly fewer cows were culled from the label 
group than from either the unvaccinated or the rolling 
groups. Analysis of milk production data 
demonstrated that, on average, cows on the label 
regimen produced a higher volume of milk (231 L) and 
more milk solids (12.36 kg) than unvaccinated cows in 
the ﬁrst 120 d of lactation. 
 
Other alternatives 
Bacteriophages 
Bacteriophage therapy can be an alternative to 
antibiotics in the fight against intramammary 
infections. Bacteriophages are viruses able to infect and 
kill bacteria (CHIBANI-CHENNOUFI et al., 2004). 
Phages were demonstrated to yield potential as new 
antimicrobial agents for veterinary applications. One 
of the well-known bacteriophages is Phage K, an anti-
staphylococcus phage, with lytic and antimicrobial 
action. Phage K has been used as prophylactic measure 
against intramammary infections caused by S. aureus. 
One of the main disadvantages of the latter phage is, 
however, that it is inhibited by milk and udder 
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secretions (O’FLAHERTY et al., 2005). Other virulent 
phages with an anti-staphylococcal activity are MSA6 
(KWIATEK et al., 2012) and CHAPk (FENTON et al., 
2013). CHAPk showed effectiveness against biofilms 
either by preventing biofilm formation or by 
disrupting established biofilms of staphylococcal 
strains associated with bovine mastitis.  
 
Nanoparticles 
Nanoparticles can be used as delivery vehicles for 
antimicrobial agents. Several researchers 
demonstrated that nanoparticles have potential as an 
alternative for the treatment of bovine mastitis. As an 
example, it has been demonstrated that silver 
nanoparticles inhibited S. aureus bacteria isolated 
from milk samples of cows with subclinical mastitis 
(DEHKORDI et al., 2011). The synergistic effect of 
silver nanoparticles and antibiotics has been evaluated 
as well. A combination of the antimicrobial 
erythromycin with silver nanoparticles was found to be 
successful against S. aureus in in vitro work of Kazemi 
et al. (2014). Other nanoparticles showing potential as 
alternative treatment for S. aureus intramammary 
infections are the tilmicosin-solid lipid nanoparticles 
(WANG et al., 2012) as well the amoxicillin 
nanoparticles that were demonstrated to be 
biologically active against S. aureus, E. coli and 
Streptococcus agalactiae (XUEFENG et al., 2009). 
Cardozo et al. (2014) revealed that nitric oxide-
nanoparticles were able to inhibit S. aureus, and in 
general could be used in the treatment and prevention 
of bovine mastitis.  
 
Cytokines 
The emergence of antibiotic resistance has 
prompted the investigation of the immunotherapeutic 
use of recombinant cytokines in the treatment of 
bovine mastitis. Cytokines are small proteins that have 
an important role in cell signaling. Some cytokines 
(such as IL-2, IFN-γ, and TNF-α) are responsible for 
stimulating innate and acquired immunity in the 
mammary gland. Unfortunately, the enhanced 
immunity was not adequate to successfully treat bovine 
mastitis. When combined with antibiotics, however, 
an additive effect was found, suggesting a synergistic 
effect and potential applications of cytokines as 
adjuvant in mastitis therapy (ALLUWAIMI, 2004). A 
more recent cytokine-derived molecule that has been 
investigated and is now commercially available is 
pegbovigrastim. Pegbovigrastim is the pegylated form 
of the cytokine bovine granulocyte colony stimulation 
factor. The cytokine bovine granulocyte colony 
stimulating factors is a cytokine that regulates the 
growth and differentiation of the precursor cell in the 
bone marrow committed to forming neutrophils. 
PEGylation increases the half-life of the protein 
messenger molecule from hours to days. In a very 
recent study of Canning et al. (2017), pegbovigrastim-
treated animals exhibited a 35% decrease in the 
incidence of clinical mastitis relative to controls during 
the first 30 days of lactation (Figure 1). 
 
Homeopathy 
Homeopathy was developed by the German 
physician Samuel Hahneman (1810) and is commonly 
referred to as a “complementary or alternative 
medicine”. Producers see advantages in the use of 
homeopathic remedies to avoid milk withdrawal 
periods (BOLDYREVA, 2003), milk residues 
(ENBERGS, 1998), or development of antibiotic 
resistance (SMITH, 2002). Still, scientific evidence for 
the effectiveness of homeopathy is lacking. Recent 
studies in veterinary medicine focused on the 
difference of the cure risk between therapy and control 
groups. While some studies found no effects of 
homeopathic therapy for mastitis (HEKTOEN, 2004; 
WERNER et al., 2010), other studies showed negative 
results in the homeopathic group (GARBE et al., 2000; 
VARSHNEY; NARESH, 2005), and still others showed 
positive results (DAY, 1986; MERCK et al., 1989). In a 
meta-analysis of Mathie and Clausen (2015), no 
significant differences were found between 
homeopathic and conventional therapies in veterinary 
medicine. Interestingly, many of the studies included 
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in the meta-analysis lacked a proper scientific 
approach. Only 28% of the studies using homeopathy 
in veterinary medicine were randomized and placebo-
controlled (CLAUSEN et al., 2013). In a very recently 
executed triple-blind, randomized controlled trial, the 
specific treatment effects of homeopathic mastitis in 
dairy cows was investigated. However, no significant 
differences were observed in time to recovery, somatic 
cell count, risk of clinical cure within 14 days after 
disease occurrence, mastitis recurrence risk, or culling 
risk. The results indicated no additional effect of 
homeopathic treatment compared with placebo 
(EBERT et al., 2017). The findings are in accordance 
with those obtained in a meta-analysis study 
conducted by Dufour and co-workers who concluded 
that homeopathic treatments are not efficient for 
management of clinical mastitis (DUFOUR et al., 
2017).  
 
 
Figure 1 – Effect of pegbovigrastim on number of periparturient cows and heifers suffering from clinical mastitis at four 
United States dairies 
Source: adapted from Canning et al. (2017) 
 
 
Bacteria and bacteria-derived inhibitory 
substances 
Several researchers suggest natural compounds 
produced by bacteria and presenting antimicrobial 
action as potential alternatives for antibiotics in the 
treatment of bovine mastitis. In 2003, field 
observations of De Vliegher et al. (2003) suggested that 
teat apex colonization by Staphylococcus chromogenes 
prepartum in dairy heifers protects the udder quarters 
against elevated somatic cell count. Interestingly, two 
out of 10 S. chromogenes isolates, both originating 
from two different teats from the same heifer, 
consistently inhibited growth of all S. aureus, 
Streptococcus dysgalactiae, and S. uberis strains, but 
none of the E. coli strains in vitro (DE VLIEGHER et 
al., 2004). Staphylococcus chromogenes belongs to the 
heterogenous group of NAS and is one of the five most 
prevalent NAS causing intramammary infections in 
bovine (VANDERHAEGHEN et al., 2015). Piccart et 
al. (2016) recently found that lactic acid bacteria 
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recovered from honeybees inhibited the in vitro 
growth of all major mastitis pathogens. Even the 
mastitis pathogens that were displaying antimicrobial 
resistance to one or more antimicrobial compounds 
were inhibited to some extend by the honey and lactic 
acid bacteria. Also, Bouchard et al. (2013) found that 
live Lactobacillus casei were able to prevent the 
internalization of S. aureus into mammary epithelial 
cells. Nisin (SEARS et al., 1992), Lacticin 3147 
(TWOMEY et al., 2000) (Figure 2) and lysostaphin 
(HENG et al., 2007) are bacteriocins that have shown 
to be effective against S. aureus.  
 
 
Figure 2 – The inhibitory effect of teat seal plus lacticin 3147 against Staphylococcus aureus DPC5246 resuspended in buffer at 
pH 7.0  
Source: based on Twomey et al. (2000) 
 
 
Animal-derived inhibitory substances 
 
The use of immunomodulators, naturally produced 
by mammals, as potential non-antibiotic antimicrobial 
agents for the treatment and prevention of bovine 
mastitis has also received attention. Lactoferrin is 
probably the most well-known natural 
immunomodulator. Lactoferrin is a glycoprotein 
found in several body secretions such as saliva, tears, 
bronchial mucus, and milk. This molecule exhibits an 
antibacterial effect against some major mastitis-
causing pathogens namely E. coli, S. aureus, 
Pseudomonas aeruginosa and Klebsiella pneumonia, 
and also NAS (HAFEZ et al., 2013) (Figure 3). Another 
example is recombinant bovine soluble CD14. 
Recombinant bovine soluble CD14 reduced the 
severity of experimental E. coli mastitis in mice (LEE et 
al., 2003). There is increasing evidence that the soluble 
form of CD14 competes with membrane-bound CD14 
for lipopolysaccharide and plays a pivotal role in 
regulating bacterial infection and septic shock caused 
by Gram-negative bacteria (LEE et al., 2003).  
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Figure 3 – Antimicrobial effect of bovine lactoferrin on E. coli, S. aureus, Streptococcus agalactiae and 
Pseudomonas aeruginosa counts after 1, 3, 6, 12, and 24 h of incubation 
 
 
Plant-derived inhibitory substances and 
medium-chain fatty acids 
Plants are promising sources of new biologically 
active agents with antimicrobial action. One of the 
major advantages of plant-derived drugs is that they do 
not induce resistance after prolonged exposure 
(DOMADIA et al., 2007). Some examples of plant-
derived natural compounds are diterpenes (FONSECA 
et al., 2013), trans-cinnamaldehyde, eugenol, 
carvacrol, and thymol (BASKARAN et al., 2009). All 
show antibacterial activity against the major mastitis 
pathogens including S. agalactiae, S. dysgalactiae, S. 
uberis, S. aureus, and E. coli.  
MCFA are another form of plant-derived 
antimicrobials. MCFA are derived from medium-
chain triglycerides. Natural sources rich in medium-
chain fatty acids are coconut oil, palm kernel oil and 
camphor tree drupe. Coconut oil is composed of 
approximately 66% of medium-chain triglycerides. 
Horse milk is another rich source of medium-chain 
triglycerides. On the contrary, the milk fats of humans, 
dogs and guinea pigs are largely made up of long-chain 
fatty acids (BRECKENRIDGE; KUKSIS, 1967). The 
milk fats of cows, sheep and goats are primarily rich in 
short-chain fatty acids. MCFA and the corresponding 
number of carbons found in medium-chain 
triglycerides are caproic acid (C6), caprylic acid (C8), 
capric acid (C10) and lauric acid (C12). Caprylic, 
capric and lauric acid have been extracted as well, 
although in relatively small amounts, from the teat 
keratin lining the teat canal (TREECE et al., 1966). 
Besides the microbicidal activity, in humans there is 
increasing evidence that MCFA have 
immunomodulating activities.  
A substantial body of literature exists on the 
antimicrobial properties of free medium- and long-
chain fatty acids and their monoglycerides that exert 
antimicrobial activity towards an array of pathogenic 
micro-organisms. Still, information on their efficacy in 
killing mastitis-causing bacteria is limited. Probably 
the first study that provided some information 
published on the microbicidal activity of long-chain 
fatty acids which are naturally present in the teat canal 
keratin towards several common mastitis pathogens 
was that of Hogan et al. (1987). A more recent study 
specifically investigated the efficacy of the MCFA 
caprylic acid (C8), and its monoglyceride, 
monocaprylin, to inactivate a number of mastitis 
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pathogens, including S. agalactiae, S. dysgalactiae, S. 
uberis, S. aureus, and E. coli (NAIR et al., 2005). 
Populations of surviving bacteria were determined at 0 
min, 1 min, 6 h, 12 h, and 24 h of incubation at a 
temperature of 39°C. Both caprylic acid and 
monocaprylin reduced growth of all five pathogens > 
5.0 log cfu/mL after 6 h of incubation (Figure 4). 
Interestingly, the microbicidal activity of fatty acids 
decreases with increasing chain length, with MCFA 
exhibiting stronger activity than long-chain fatty acids 
(WANG; JOHNSON, 1992; ISAACS et al., 1995). The 
decreasing effectiveness with longer chain length is 
most probably related to increased hydrophobicity and 
decreased solubility. Inhibitory fatty acids must be 
sufficiently water soluble to reach an effective 
concentration in the aqueous solution and yet be 
sufficiently hydrophobic to interact with hydrophobic 
proteins or lipids on the bacterial cell surface (WANG; 
JOHNSON, 1992). The latter reasoning might hold 
true for the different MCFA mutually as well (NAIR et 
al., 2005). 
 
 
 
 
 
Figure 4 – Effect of 50 mM of the medium-chain fatty acid (MCFA) caprylic acid on Streptococcus uberis, Staphylococcus aureus, 
Escherichia coli and Streptococcus dysgalactiae in milk. Surviving bacterial populations (expressed in log cfu/mL) in 
milk samples stored at 39°C for 24 h were enumerated at specified time points on tryptic soy agar plates containing 
0.6% yeast extract  
Source: adapted from Nair et al. (2005) 
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The exact mechanism behind the bactericidal 
activity of free fatty acids on bacteria has not yet been 
unraveled. Cellular membranes have long been 
regarded as a primary target for antimicrobial fatty 
acids. Monoglycerides have been demonstrated to 
penetrate into the bacteria as non-ionic surfactants 
and to incorporate themselves into the bacterial 
plasma membrane, thereby altering membrane 
permeability and affecting transport of nutrients. 
Electron microscopic studies with 43 bacterial cells 
exposed to monoglycerides have shown plasma 
membrane disintegration leaving the peptidoglycan 
cell wall intact (BERGSSON et al., 1998). Other 
studies indicated that micromolar concentrations of 
fatty acids can affect the activity of enzymes in the 
cell membrane (WARTH, 1989; VIEGAS; SA-
CORREIA, 1991). MCFA, in particular, have also 
been hypothesized to diffuse into bacterial cells in 
their undissociated form and dissociate within the 
protoplasm, thereby leading to intracellular 
acidification (SUN et al., 2002). A lower intracellular 
pH can lead to inactivation of intracellular enzymes 
(VIEGAS; SA-CORREIA, 1991), and inhibition of 
amino acid transport (FREESE et al., 1973). At 
sublethal concentrations, monoglycerides such as 
monolaurin can interfere with bacterial signal 
transduction, and inhibit the expression of virulence 
factors and antibiotic resistance genes (PROJAN et 
al., 1994; RUZIN; NOVICK, 1998).  
The sensitivity to fatty acids seems to vary among 
bacterial species and possibly also among strains 
within a species. In general, Gram-negative bacteria 
like E. coli are less sensitive to the antimicrobial 
effect of fatty acids and monoglycerides than Gram-
positive bacteria (KABARA, 1978; MONK et al., 
1996). Also, S. aureus seems to be more tolerant than 
mastitis-causing streptococci such as S. agalactiae, S. 
dysgalactiae, and S. uberis (NAIR et al., 2005). In the 
latter study, caprylic acid at 100 Mm and 
monocaprylin at 50 mM levels resulted in a rapid 
decline (4 to 6 log cfu/ml) in the populations of 
streptococci after 1 min of treatment. At the same 
time point, the effect of monocaprylin on E. coli and 
S. aureus was clearly less pronounced (3 to 4 log 
cfu/ml). The comparatively lesser instantaneous 
antibacterial effect of MCFA on Gram-negative 
bacteria can possibly be attributed to the well-known 
differences in cell wall structure between Gram-
positive and Gram-negative bacteria. With respect to 
S. aureus, it is well established that some strains are 
able to produce slime once they start growing 
(SUTRA et al., 1990). It is very plausible that the 
layer of exopolysaccharide or pseudocapsule slime 
surrounding them could interfere with the lipids 
coming in direct contact with the bacterial cell 
membranes and exerting the antimicrobial activity. 
The inhibitory activity of fatty acids and 
monoglycerides probably also depends on the 
composition of the medium in which they are 
supposed to act. Wang and Johnson (1992) found 
that although lauric acid and its monoglyceride 
monolaurin were bactericidal against Listeria 
monocytogenesis in brain-heart infusion broth, none 
of the two were still inhibitory in milk. Certain 
nutrients in relatively high concentrations such as 
lipophilic proteins (e.g. albumin), fat globules, 
starch, or others could interact with fatty acids and 
thereby decrease their bioavailability (KABARA, 
1978). Glassman (1949) reported that proteins 
reduce the bactericidal activity of surface-active 
agents like monoglycerides due to the formation of 
lipid-protein complexes. On the contrary, reduced 
antimicrobial activity of MCFA when evaluated in 
milk could not be observed by Nair et al. (2005). 
The discrepancy in the findings between those 
two studies might again be due to differences in 
chain length between the MCFA that were tested. 
Caprylic acid, an 8-carbon MCFA, is less 
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hydrophobic and potentially more soluble than 
lauric acid, a 12-carbon MCFA, and could therefore 
be more effective in killing bacteria under less 
optimal conditions, i.e. milk, than MCFA with a 
longer chain (NAIR et al., 2005). 
Although a plethora of information is available 
on the immunomodulating effects of MCFA in 
humans, little information is available on these 
effects in the bovine. Piepers and De Vliegher (2013) 
explored the effect of commercially available orally 
supplemented MCFA (Aromabiotic®, Vitamex n.v., 
Drongen, Belgium) to heifers and multiparous cows 
starting at 6 to 8 weeks prior to calving on the blood 
and milk neutrophil apoptosis at 1 to 3 days after 
calving in a double-blinded clinical trial. 
Neutrophils play an important role in the first line 
immune defense of the mammary gland (RAINARD 
et al., 2006). Apoptosis of bovine neutrophils implies 
an impaired phagocytotic and oxidative burst 
activity (MEHRZAD et al., 2004). A reduction in 
neutrophil apoptosis has therefore been proposed to 
be beneficial for the elimination of the bacteria in the 
early stages of intramammary infections as increased 
numbers of more viable neutrophils enhance the 
defense against the invading bacteria (DIBBERT et 
al., 1999). In this trial, twelve lactating cows and 10 
end-term heifers were randomly assigned to either 
an untreated control (n = 11) or MCFA 
supplemented (treated) group (n = 11). Oral 
supplementation with MCFA started at dry-off for 
multiparous cows and 7 weeks prior to expected 
calving date for the end-term heifers. Interestingly, 
oral supplementation of MCFA to heifers and 
multiparous cows suppressed the natural drop in the 
systemic as well as the local innate immunity shortly 
after calving as evident from the better neutrophil 
quality in both blood and milk (Figure 5). In the 
control animals, blood neutrophil apoptosis 
significantly increased between start of 
supplementation and the first days after calving, 
whereas no substantial change in blood neutrophil 
apoptosis could be observed in the treated animals. 
Also, the proportion of apoptotic milk neutrophils 
in early lactation was lower in the treated group 
compared to the control group. The mechanism 
behind these potential immunomodulating effects is 
unknown and even more intriguing than the 
questions related to the microbicidal activity of 
MCFA. In humans, MCFA such as lauric acid seems 
to have moderate to strong antioxidant properties, 
delaying or even preventing cell/tissue damage due 
to oxidative stress (BELLINATIE-PIRES et al., 1993; 
HENRY et al., 2002; VERSLEIJEN et al., 2005). 
Oxidative stress is the result of an imbalance between 
increased production of reactive oxygen species 
(ROS) causing cell and tissue damage, and reduced 
availability of antioxidants usually protecting cells 
from the damaging effects of ROS. Besides their anti-
oxidative activities, caprylic and lauric acid also 
exhibit anti-inflammatory properties via the 
inhibition of cyclo-oxygenase I (COX-I) and II 
(COX-II) (HENRY et al., 2002). 
When looking at the potential applications of 
MCFA in practice, treatment of mastitis should be 
distinguished from prevention of mastitis: 
Treatment of mastitis. The effectiveness of MCFA 
in inhibiting the most common mastitis pathogens 
under in vitro circumstances looks promising in 
view of the development of novel strategies in the 
control of mastitis. Similar to what has already been 
done with bacteriocins (RYAN et al., 1999), MCFA 
could be incorporated in intramammary infusions 
whether or not combined with internal teat sealants 
used at dry-off. Still, there is much more research 
required to ascertain the in vivo effectiveness as well 
as their potential negative effects on the udder tissue. 
In addition, MCFA might affect the organoleptic 
and functional properties of milk which would 
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obviously make the use of MCFA as microbicidal less 
desirable (AL-SHABIBI et al., 1964). Oral 
supplementation of MCFA will most likely not affect 
the organoleptic properties of milk, but will, as a 
drawback, probably neither result in an increase of 
the antibacterial properties of milk. Grummer and 
Socha (1989) evaluated the effects of medium-chain 
triglycerides supplementation on milk fatty acid 
composition. Although changes in milk fatty acid 
composition were observed, they were minor and 
mostly unexplained. In contrast to long-chain fatty 
acids, which are absorbed via the lymphatic system 
as chylomicrons, MCFA are absorbed via the hepatic 
portal vein. As a consequence, the efficiency of 
transfer of absorbed MCFA to milk is low. 
Prevention of mastitis. Oral supplementation of 
MCFA could offer an opportunity to stimulate 
cellular immunity and support cows in meeting their 
every-day challenges, particularly in the critical  
period around calving. Negative energy balance and 
increased milk production demands in high yielding 
dairy cows during transition often result in an 
accumulation of ROS that exceeds the antioxidant 
capabilities of the cow. The increased oxidative stress 
during transition has been proposed a number of 
times as a major underlying factor of the 
immunosuppression that cows suffer from around 
parturition (BERNABUCCI et al., 2005; CASTILLO 
et al., 2005; SORDILLO; AITKEN, 2009). As 
antioxidants, MCFA could possibly help in 
minimizing the detrimental effects of the excessive 
accumulation of ROS and thus keeping oxidative 
stress and negative effects on the cellular immune 
functions under control. Because of their anti-
inflammatory properties, MCFA could also be 
beneficial in  channeling the sometimes overzealous 
inflammatory response to intramammary infections 
that occurs during transition, thereby limiting udder 
tissue damage and milk production losses 
(BURVENICH et al., 2007). However, further 
research is needed to value the relevance of both the 
anti-oxidative and anti-inflammatory effects of 
MCFA in terms of potential reduction of antibiotic 
usage on dairy farms in relation to udder health. 
 
Conclusions 
Currently, the administration of antimicrobials is 
still the most common method to treat bovine 
mastitis. Still, this kind of strategy has some 
important disadvantages including the potential 
development of antimicrobial resistance in both 
animal and human pathogens, and the risk for 
antimicrobial residues in milk. Therefore, a wide 
range of alternatives to antimicrobials have been 
investigated by several groups of researchers in order 
to find an effective and equivalent approach for the 
treatment of bovine mastitis. Bacteriophages, 
vaccines, nanoparticles, cytokines, and natural 
compounds of plants, animals and bacteria are some 
examples of potentially valid substitutes for 
antimicrobials. For most of those alternatives, in 
vitro studies showed encouraging results but more 
research, primarily conducted in vivo, is still lacking 
though critical and required. Currently, vaccination 
in the periparturient period against mastitis caused 
by E. coli and S. aureus, injection of pegbovigrastim 
in periparturient period and oral supplementation of 
MCFA across dry period are the only alternatives 
that have yet been shown to yield decent prevention, 
though not curative efficacy in vivo. 
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Figure 5 – Percentage apoptotic blood polymorphonuclear neutrophilic leukocytes in both control 
and medium-chain fatty acid (MCFA) supplemented animals between the start of 
supplementation [6-8 weeks before expected calving date (= at dry-off)] and early lactation 
(1-3 days in milk) 
Source: adapted from Piepers and De Vliegher (2013) 
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